January 26, 2023 02:41 PM EST
Pharma
FDA+
Coronavirus

FDA cuts off use for As­traZeneca’s Covid-19 ther­a­py Evusheld

Lei Lei Wu

News Reporter

The FDA has stopped use of an­oth­er drug as a re­sult of the new coro­n­avirus vari­ants. On Thurs­day, the agency an­nounced that As­traZeneca’s an­ti­body com­bo …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times